Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    MOBIDIAG (EGFF)

    Tools for diagnosing COVID-19

    Support for the innovative medtech company Mobidiag which develops and produces diagnostic tests and devices for infectious diseases, including COVID-19.

    Status
    First signature
    Signed
    14/05/2019
    Amount
    EUR 25,000,000
    Countries
    Finland
    Sector(s)
    Services
    See more

    Signature(s)

    Amount
    € 25,000,000
    Countries
    Sector(s)
    Finland : € 25,000,000
    Services : € 25,000,000
    Signature date(s)
    14/05/2019 : € 12,500,000
    14/05/2019 : € 12,500,000
    Link to source
    Data sheet

    Summary sheet

    Release date
    11 March 2019
    Status
    Reference
    Signed | 14/05/2019
    20190062
    Project name
    Promoter - financial intermediary
    MOBIDIAG (EGFF)
    MOBIDIAG OY
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 25 million
    EUR 66 million
    Location
    Sector(s)
    • Services - Professional, scientific and technical activities
    Description
    Objectives

    The project consists of the financing of Mobidiag, an innovative medtech company based in Finland. This financing will help Mobidiag to develop new diagnostic tests for infectious diseases.

    The proposed transaction will support research and development (R&D) investments that are required in order to further advance the promoter's product pipeline and bring the products to market.

    Environmental aspects
    Procurement

    The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

    The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

    Link to source
    Summary sheet

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Documents

    Environmental and Social Data Sheet (ESDS) - MOBIDIAG (EGFF)
    Publication Date
    5 Apr 2022
    Document language
    Main Topic
    Lending
    Document Number
    92360056
    Document Focus
    Environmental Information
    Project Number
    20190062
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now
    scoreboard - EUROPEAN GROWTH FINANCE FACILITY
    Publication Date
    13 Sep 2019
    Document Language
    English
    Main Topic
    lending
    Document Number
    122912044
    Document Focus
    EFSI legal requirements
    Document Type
    Scoreboard
    Project Number
    20180667
    Last update
    19 Aug 2020
    Sector(s)
    Services
    Countries
    Bulgaria, Kenya, Ghana, Mexico, Philippines
    Publicly available
    Download now

    News & Stories

    Inside the project

    How and Why

    Testing and screening

    Why

    • The coronavirus pandemic has created a need for fast, reliable, large-scale testing solutions that could be operated also by people without training in diagnostics
    • The field of diagnostics will be critical in the fight against pandemics like the coronavirus and in the future.

    How

    • Mobidiag offers a comprehensive range of fast, reliable and cost-effective molecular diagnostic solutions for the detection of most clinically relevant bacteria, parasites, viruses and antibiotic resistances
    • The EIB financing supports the development of two testing machines for the rapid molecular diagnostics of coronavirus infection: Novodiag and Amplidiag
    • Based on well-established qPCR and microarray technologies, these machines combine high quality and affordable costs and offer a complete solution for rapid molecular diagnostics of coronavirus infection.

    Impact

    A complete solution for COVID-19 infection

    • Mobidiag makes in vitro diagnostics fast, accurate and accessible to improve quality and efficiency of healthcare systems, and help prevent the spreading of antibiotic resistances 
    • Novodiag, a “random access platform”, allows even non-skilled people to simply use a pipet to drop a sample into a cartridge, insert the cartridge into the machine and press a button to run the test
    • Amplidiag, a larger machine, is used for high-throughput screening in labs.
       
    This novel coronavirus situation is very severe. All the companies in our field need to act rapidly. We need rapid diagnostic tools to detect the novel coronavirus, and we are taking part in that fight.
    Tuomas Tenkanen

    Head of Mobidiag

    The first EIB loan €15 million was signed in 2016 under the InnovFin Infectious Diseases Finance Facility.

    Play video

    1:06

    custom-preview

    Story

    In the front line against COVID-19

    The second EIB quasi-equity deal for €25 million was signed in 2019 under the European Fund for Strategic Investment.

    When the novel coronavirus hit, Mobidiag, which operates in Finland and France, turned its full attention to the most pressing diagnostics issue across the world.

    Mobidiag has marketed a test in Europe to detect antibodies against SARS-CoV-2, the virus responsible for Covid-19 infections. This test was developed by its Chinese partner, Autobio Diagnostics. Antibodies testing is important because it can detect whether a patient was infected in the past – not only whether the person is currently infected. As studies show that large numbers of people may have had the coronavirus without showing symptoms, testing for antibodies will be crucial to understand the spread of the virus and develop appropriate responses. So Mobidiag has put all its efforts into offering a complete solution for coronavirus detection with its Novodiag and Amplidiag coronavirus tests.

    “We will shortly be moving away from just diagnosing the patients infected with the virus into identifying those people who have already encountered the disease and developed immunity. Such information will be key in making decisions when is it safe to dismantle the current restrictions of movement and isolation,” says Auvo Kaikkonen, a senior life science specialist at the European Investment Bank who has been following the developments at Mobidiag.    

    The field of diagnostic tools is just one of many healthcare areas in which the Bank invests. Whether through the development of vaccines or therapeutics, the EIB has worked hard to get the financing quickly to the most promising ones.

    By supporting the development of in-vitro testing platforms and facilities, we have been able to provide a crucial service in Europe in these difficult times.
    Auvo Kaikkonen

    EIB Senior Life Science Specialist

    Videos

    Photogallery

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications